Full Text | PDF

Share on tweeters Share on facebook Share on linkedin Share on googleplus

Theranostics 2020; 10(12):5501-5513. doi:10.7150/thno.45554 This issue Cite

Review

Liquid biopsy for infectious diseases: a focus on microbial cell-free DNA sequencing

Dongsheng Han1,2,3*, Rui Li1,2,3*, Jiping Shi1,3,4, Ping Tan1,2,3, Rui Zhang1,3✉, Jinming Li1,2,3✉

1. National Center for Clinical Laboratories, Beijing Hospital, National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, P.R. China.
2. Graduate School, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, P.R. China.
3. Beijing Engineering Research Center of Laboratory Medicine, Beijing Hospital, Beijing, P.R. China.
4. Peking University Fifth School of Clinical Medicine, National Center for Clinical Laboratories, National Center of Gerontology, Beijing Hospital, Beijing, China.
*These authors contributed equally to this work.

✉ Corresponding authors: Jinming Li, Ph.D., and Rui Zhang, Ph.D., National Center for Clinical Laboratories, Beijing Hospital, No.1 Dahua Road, Dongdan, Beijing 100730, People's Republic of China. Fax: +86-10-65212064. E-mail: jmliorg.cn (Jinmin More

Citation:
Han D, Li R, Shi J, Tan P, Zhang R, Li J. Liquid biopsy for infectious diseases: a focus on microbial cell-free DNA sequencing. Theranostics 2020; 10(12):5501-5513. doi:10.7150/thno.45554. https://www.thno.org/v10p5501.htm
Other styles

File import instruction

Abstract

Graphic abstract

Metagenomic next-generation sequencing (mNGS) of microbial cell-free DNA (mcfDNA sequencing) is becoming an attractive diagnostic modality for infectious diseases, allowing broad-range pathogen detection, noninvasive sampling, and rapid diagnosis. At this key juncture in the translation of metagenomics into clinical practice, an integrative perspective is needed to understand the significance of emerging mcfDNA sequencing technology. In this review, we summarized the actual performance of the mcfDNA sequencing tests recently used in health care settings for the diagnosis of a variety of infectious diseases and further focused on the practice considerations (challenges and solutions) for improving the accuracy and clinical relevance of the results produced by this evolving technique. Such knowledge will be helpful for physicians, microbiologists and researchers to understand what is going on in this quickly progressing field of non-invasive pathogen diagnosis by mcfDNA sequencing and promote the routine implementation of this technique in the diagnosis of infectious disease.

Keywords: microbial cfDNA, cell-free DNA sequencing, metagenomics, next-generation sequencing, microbiology.

Citation styles

APA
Han, D., Li, R., Shi, J., Tan, P., Zhang, R., Li, J. (2020). Liquid biopsy for infectious diseases: a focus on microbial cell-free DNA sequencing. Theranostics, 10(12), 5501-5513. https://doi.org/10.7150/thno.45554.

ACS
Han, D.; Li, R.; Shi, J.; Tan, P.; Zhang, R.; Li, J. Liquid biopsy for infectious diseases: a focus on microbial cell-free DNA sequencing. Theranostics 2020, 10 (12), 5501-5513. DOI: 10.7150/thno.45554.

NLM
Han D, Li R, Shi J, Tan P, Zhang R, Li J. Liquid biopsy for infectious diseases: a focus on microbial cell-free DNA sequencing. Theranostics 2020; 10(12):5501-5513. doi:10.7150/thno.45554. https://www.thno.org/v10p5501.htm

CSE
Han D, Li R, Shi J, Tan P, Zhang R, Li J. 2020. Liquid biopsy for infectious diseases: a focus on microbial cell-free DNA sequencing. Theranostics. 10(12):5501-5513.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image

©2024 Ivyspring International Publisher. Terms of use